.
BioEnterprise

Abeona Therapeutics Announces Approval of ABO-102 Dose Escalation For Second Cohort In Phase 1/2 Clinical Trial

Abeona Therapeutics announces that the Data Safety Monitoring Board has reviewed the initial safety data from the low dose cohort in the Phase 1/2 clinical trial of ABO-102 and authorized the clinical trial to proceed with enrollment and dose escalation for the second cohort.

Read More  >
Hello. Add your message here.